Physician profile
Monica M Van Acker
NPI 1346689700
$5,601.49
in general payments reported to CMS, 2019-2025
31 companies · $1,843 in 2025
The $1,843 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $109 · 2021: $22.39 · 2022: $262 · 2023: $1,056 · 2024: $1,520 · 2025: $1,843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,980 · Education: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,979.77 |
| Education | $437.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $868.86 | 2022-2025 | Tremfya, Xarelto |
| Abbvie INC. | $579.21 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Dermavant Sciences, INC. | $482.73 | 2023-2024 | Vtama |
| Genzyme Corporation | $368.35 | 2019-2025 | |
| Amgen INC. | $357.87 | 2024-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $321.76 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $314.13 | 2022-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $279.94 | 2019-2025 | |
| Lilly USA, LLC | $259.23 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $205.49 | 2020-2025 | Odomzo, Blu-U, Ilumya |
| E.R. Squibb & Sons, L.L.C. | $196.40 | 2022-2025 | Sotyktu |
| Pfizer INC. | $190.51 | 2019-2025 | |
| Organon LLC | $181.89 | 2024-2025 | Vtama, Hadlima |
| Ucb, INC. | $134.06 | 2019-2025 | Cimzia, Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.93 | 2022-2025 | Spevigo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $100.24 | 2020-2025 | Nemluvio, Twyneo, Oracea |
| Mayne Pharma Commercial LLC | $94.48 | 2019-2025 | |
| Incyte Corporation | $82.14 | 2024-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $74.30 | 2019-2024 | Cabtreo |
| Kerecis Limited | $49.86 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Almirall LLC | $47.46 | 2019 | |
| Strata Skin Sciences, INC. | $42.11 | 2019-2025 | Xtrac |
| Leo Pharma INC. | $38.17 | 2024-2025 | Adbry |
| Dusa Pharmaceuticals, INC. | $33.58 | 2019 | |
| Celgene Corporation | $30.48 | 2019 | |
| Vyne Pharmaceuticals INC. | $27.67 | 2020 | |
| Allergan, INC. | $27.24 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $24.67 | 2019 | |
| Mimedx Group, INC. | $24.26 | 2025 | |
| Aclaris Therapeutics, INC. | $16.36 | 2019 | |
| Genentech USA, INC. | $16.11 | 2023 | Xolair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Van Acker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.